Botanical Ingredient

Norcantharidin Safety Tips

Handling of Norcantharidin should only be performed by personnel trained and familiar with handling of potent active pharmaceutical ingredients. Moderate to severe irritant to the skin and eyes.

References

• 1. Cantharidin as an Antitumor Agent: A Retrospective Review.
  Deng LP, Dong J, Cai H, Wang W.Curr Med Chem. 2012 Nov 26. [Epub ahead of print]
• 2. Erratum to: The anti-proliferative effects of norcantharidin on human HepG2 cells in cell culture.
  Chang C, Zhu Y, Tang X, Tao W.Mol Biol Rep. 2013 Jan;40(1):739. doi: 10.1007/s11033-012-2336-y. No abstract is available.
• 3. Norcantharidin suppresses cell growth and migration with enhanced anticancer activity of gefitinib and cisplatin in human non-small cell lung cancer cells.
  Lee YC, Lee LM, Yang CH, Lin AM, Huang YC, Hsu CC, Chen MS, Chi CW, Yin PH, Kuo CD, Liao JF, Lee HC.Oncol Rep. 2013 Jan;29(1):237-43. doi: 10.3892/or.2012.2118. Epub 2012 Oct 31.
• 4. Preparation, characterization and anticancer activity of norcantharidin-loaded poly(ethylene glycol)-poly(caprolactone) amphiphilic block copolymer micelles.
  Chen SF, Lu WF, Wen ZY, Li Q, Chen JH.Pharmazie. 2012 Sep;67(9):781-8.
• 5. Norcantharidin facilitates LPS-mediated immune responses by up-regulation of AKT/NF-κB signaling in macrophages.
  Zhao Q, Qian Y, Li R, Tan B, Han H, Liu M, Qian M, Du B.PLoS One. 2012;7(9):e44956. doi: 10.1371/journal.pone.0044956. Epub 2012 Sep 11.
• 6. Clinical report on transarterial neoadjuvant chemotherapy of malignant fibrous histiocytoma in soft tissue.
  Guo J, Cui Q, Liu C, Sui J, Jiang N, Zhou J, Li D, Zeng Y.Clin Transl Oncol. 2012 Sep 14. [Epub ahead of print]
• 7. Preclinical evaluations of norcantharidin-loaded intravenous lipid microspheres with low toxicity.
  Lin X, Zhang B, Zhang K, Zhang Y, Wang J, Qi N, Yang S, He H, Tang X.Expert Opin Drug Deliv. 2012 Dec;9(12):1449-62. doi: 10.1517/17425247.2012.724675. Epub 2012 Sep 13.
• 8. Hepatocyte-Targeted Delivery Using pH-Sensitive Liposomes Loaded with Lactosylnorcantharidin Phospholipid Complex: Preparation, Characterization, and Therapeutic Evaluation In Vivo and In Vitro.
  Qiao-Ling Z, Yi Z, Min G, Di-Jia Y, Xiao-Feng Z, Yang L, Jing-Yu X, Ying W, Zong-Lin G, Kong-Lang X, Ai-Jun Z, Wei-Liang C, Lin-Sen S, Xue-Nong Z, Qiang Z.Curr Med Chem. 2012 Nov 1;19(33):5754-63.
• 9. Induction of apoptosis in human Hep3B hepatoma cells by norcantharidin through a p53 independent pathway via TRAIL/DR5 signal transduction.
  Yeh CH, Yang YY, Huang YF, Chow KC, Chen MF.Chin J Integr Med. 2012 Sep;18(9):676-82. doi: 10.1007/s11655-012-1206-8. Epub 2012 Aug 31.
• 10. Suppression of lymphangiogenesis in human lymphatic endothelial cells             by simultaneously blocking VEGF-C and VEGF-D/VEGFR-3 with norcantharidin.
  Liu ZY, Qiu HO, Yuan XJ, Ni YY, Sun JJ, Jing W, Fan YZ.Int J Oncol. 2012 Nov;41(5):1762-72. doi: 10.3892/ijo.2012.1603. Epub 2012 Aug 23.
• 11. Norcantharidin enhances bortezomib-antimyeloma activity in multiple myeloma cells in vitro and nude mouse xenografts.
  Du HF, Yu LJ, Meng YF, Lv HY, Meng J, Song XN, Zhang JQ.Leuk Lymphoma. 2012 Sep 3. [Epub ahead of print]
• 12. Synthesis and anticancer activity of a series of norcantharidin analogues.
  Tarleton M, Gilbert J, Sakoff JA, McCluskey A.Eur J Med Chem. 2012 Aug;54:573-81. doi: 10.1016/j.ejmech.2012.06.010. Epub 2012 Jun 15.
• 13. Norcantharidin Induces HL-60 Cells Apoptosis In Vitro.
  Jiang YM, Meng ZZ, Yue GX, Chen JX.Evid Based Complement Alternat Med. 2012;2012:154271. doi: 10.1155/2012/154271. Epub 2012 Jun 24.
• 14. Norcantharidin triggers cell death and DNA damage through S-phase arrest and ROS-modulated apoptotic pathways in TSGH 8301 human urinary bladder carcinoma cells.
  Yu CC, Ko FY, Yu CS, Lin CC, Huang YP, Yang JS, Lin JP, Chung JG.Int J Oncol. 2012 Sep;41(3):1050-60. doi: 10.3892/ijo.2012.1511. Epub 2012 Jun 7.
• 15. Novel norcantharidin-loaded liver targeting chitosan nanoparticles to enhance intestinal absorption.
  Bei YY, Chen XY, Liu Y, Xu JY, Wang WJ, Gu ZL, Xing KL, Zhu AJ, Chen WL, Shi LS, Wang Q, Zhang XN, Zhang Q.Int J Nanomedicine. 2012;7:1819-27. doi: 10.2147/IJN.S29958. Epub 2012 Apr 3.
• 16. Pharmacokinetics, tissue distribution, and metabolites of a polyvinylpyrrolidone-coated norcantharidin chitosan nanoparticle formulation in rats and mice, using LC-MS/MS.
  Ding XY, Hong CJ, Liu Y, Gu ZL, Xing KL, Zhu AJ, Chen WL, Shi LS, Zhang XN, Zhang Q.Int J Nanomedicine. 2012;7:1723-35. doi: 10.2147/IJN.S29696. Epub 2012 Apr 2.
• 17. Small-molecule synthetic compound norcantharidin reverses multi-drug resistance by regulating Sonic hedgehog signaling in human breast cancer cells.
  Chen YJ, Kuo CD, Chen SH, Chen WJ, Huang WC, Chao KS, Liao HF.PLoS One. 2012;7(5):e37006. doi: 10.1371/journal.pone.0037006. Epub 2012 May 15.
• 18. Norcantharidin enhances ABT-737-induced apoptosis in hepatocellular carcinoma cells by transcriptional repression of Mcl-1.
  Zhang S, Li G, Ma X, Wang Y, Liu G, Feng L, Zhao Y, Zhang G, Wu Y, Ye X, Qin B, Lu J.Cell Signal. 2012 Sep;24(9):1803-9. doi: 10.1016/j.cellsig.2012.05.009. Epub 2012 May 17.
• 19. Effect of norcantharidin on the human breast cancer bcap-37 cells.
  Liu D, Shi P, Yin X, Chen Z, Zhang X.Connect Tissue Res. 2012;53(6):508-12. doi: 10.3109/03008207.2012.694928. Epub 2012 Jul 20.
• 20. Uptake and transport of a novel anticancer drug-delivery system: lactosyl-norcantharidin-associated N-trimethyl chitosan nanoparticles across intestinal Caco-2 cell monolayers.
  Guan M, Zhu QL, Liu Y, Bei YY, Gu ZL, Zhang XN, Zhang Q.Int J Nanomedicine. 2012;7:1921-30. doi: 10.2147/IJN.S30034. Epub 2012 Apr 11.